Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity.
about
A chemical screen identifies small molecules that regulate hepcidin expression.The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies.CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target.Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.Nuclear localization of the CK2α-subunit correlates with poor prognosis in clear cell renal cell carcinoma.Knowledge-guided gene prioritization reveals new insights into the mechanisms of chemoresistance.Casein kinases as potential therapeutic targets.Casein Kinase II (CK2), Glycogen Synthase Kinase-3 (GSK-3) and Ikaros mediated regulation of leukemia.Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia.Regulation of cellular proliferation in acute lymphoblastic leukemia by Casein Kinase II (CK2) and Ikaros.Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways.Cancer-type dependent expression of CK2 transcripts.Therapeutic targeting of CK2 in acute and chronic leukemias.Under-expression of CK2β subunit in ccRCC represents a complementary biomarker of p-STAT3 Ser727 that correlates with patient survival.Inhibition of Casein Kinase 2 Disrupts Differentiation of Myeloid Cells in Cancer and Enhances the Efficacy of Immunotherapy in MiceCX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism
P2860
Q34345426-D38DB18D-65DD-4A84-9A82-7E5DBB823069Q34471660-B2CC5E4E-506F-4951-9734-89FDFEEC436EQ36263671-090DA5FF-EE5C-4E6F-8781-1010A39A648FQ36738818-2A30A3E5-3BBE-44BE-A307-B2E009744CADQ37702141-AD700C12-B7E3-4C74-84AE-1E79539E0301Q38628538-0173984F-F40A-4FCA-9CC2-AFE8AE1ABF7DQ38632634-9B1ACC53-8AF0-4EF7-9DAA-653F53D29730Q38721782-FCD97823-B712-49EA-8EC3-546135BB457FQ38754441-1005C311-CA04-4CF7-B10F-505366D0450BQ38964075-502C7463-4268-4034-BEA2-03FA30660DFCQ42284390-10D8C28E-CE9D-486D-AE12-05C894DBB00FQ47114281-1531FE40-DDAE-491F-8452-05D97F8812F2Q47677919-1C06B44F-034D-4149-B9CF-E643913FF13BQ50042975-629B6F42-6EE1-43DD-ADF7-B45762B3B46BQ56872957-FEE60E39-98C9-40AF-998D-41E6484EA255Q58710589-6C50069F-4A69-4DFA-BFBB-DB48450CF0CA
P2860
Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Inhibition of protein kinase C ...... orubicin-induced cytotoxicity.
@en
Inhibition of protein kinase C ...... orubicin-induced cytotoxicity.
@nl
type
label
Inhibition of protein kinase C ...... orubicin-induced cytotoxicity.
@en
Inhibition of protein kinase C ...... orubicin-induced cytotoxicity.
@nl
prefLabel
Inhibition of protein kinase C ...... orubicin-induced cytotoxicity.
@en
Inhibition of protein kinase C ...... orubicin-induced cytotoxicity.
@nl
P2093
P2860
P50
P356
P1476
Inhibition of protein kinase C ...... orubicin-induced cytotoxicity.
@en
P2093
Alessandra Brancalion
Carmela Gurrieri
Fausto Adami
Federica Lessi
Laura Bonaldi
Laura Pavan
Laura Quotti Tubi
Renato Zambello
Roberta Bertorelle
P2860
P2888
P356
10.1186/1756-8722-6-78
P577
2013-10-12T00:00:00Z
P5875
P6179
1037264231